Vero cell upstream bioprocess development for the production of viral vectors and vaccines.
Bioreactor
Cell culture
Microcarrier
Optimization
Process development
Suspension culture
Vaccines
Vero
Virus production
Journal
Biotechnology advances
ISSN: 1873-1899
Titre abrégé: Biotechnol Adv
Pays: England
ID NLM: 8403708
Informations de publication
Date de publication:
15 11 2020
15 11 2020
Historique:
received:
24
06
2020
revised:
28
07
2020
accepted:
30
07
2020
pubmed:
10
8
2020
medline:
21
10
2020
entrez:
10
8
2020
Statut:
ppublish
Résumé
The Vero cell line is considered the most used continuous cell line for the production of viral vectors and vaccines. Historically, it is the first cell line that was approved by the WHO for the production of human vaccines. Comprehensive experimental data on the production of many viruses using the Vero cell line can be found in the literature. However, the vast majority of these processes is relying on the microcarrier technology. While this system is established for the large-scale manufacturing of viral vaccine, it is still quite complex and labor intensive. Moreover, scale-up remains difficult and is limited by the surface area given by the carriers. To overcome these and other drawbacks and to establish more efficient manufacturing processes, it is a priority to further develop the Vero cell platform by applying novel bioprocess technologies. Especially in times like the current COVID-19 pandemic, advanced and scalable platform technologies could provide more efficient and cost-effective solutions to meet the global vaccine demand. Herein, we review the prevailing literature on Vero cell bioprocess development for the production of viral vectors and vaccines with the aim to assess the recent advances in bioprocess development. We critically underline the need for further research activities and describe bottlenecks to improve the Vero cell platform by taking advantage of recent developments in the cell culture engineering field.
Identifiants
pubmed: 32768520
pii: S0734-9750(20)30110-5
doi: 10.1016/j.biotechadv.2020.107608
pmc: PMC7405825
pii:
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107608Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Virol. 2011 Jul;85(13):6579-88
pubmed: 21543506
Vaccine. 2014 May 19;32(24):2767-9
pubmed: 24583007
Mol Ther Methods Clin Dev. 2019 Aug 29;15:63-71
pubmed: 31649956
Proc Soc Exp Biol Med. 1969 Nov;132(2):670-8
pubmed: 4982209
Biochem Biophys Res Commun. 2005 Mar 25;328(4):1034-42
pubmed: 15707982
AIDS Res Ther. 2017 Sep 12;14(1):55
pubmed: 28893277
Biotechnol Prog. 2019 Jan;35(1):e2687
pubmed: 30009565
Metab Eng. 2007 May;9(3):241-51
pubmed: 17240181
J Clin Microbiol. 1990 Feb;28(2):283-6
pubmed: 2179260
Biotechnol J. 2018 Mar;13(3):e1700211
pubmed: 28976642
Expert Rev Vaccines. 2009 May;8(5):607-18
pubmed: 19397417
Vaccine. 2007 Jan 2;25(1):19-24
pubmed: 16919374
Biologicals. 2007 Oct;35(4):221-6
pubmed: 17400474
J Infect Dis. 2013 Jun 1;207(11):1743-52
pubmed: 23532101
Hum Gene Ther. 2015 Aug;26(8):560-71
pubmed: 26176404
Biologicals. 2002 Dec;30(4):303-14
pubmed: 12421588
Appl Microbiol Biotechnol. 2009 Nov;85(1):53-63
pubmed: 19521697
Vaccine. 2008 Jun 19;26(26):3305-11
pubmed: 18486286
Front Bioeng Biotechnol. 2019 Apr 17;7:78
pubmed: 31058145
Vaccine. 2018 May 24;36(22):3140-3145
pubmed: 28343780
Cytotechnology. 2006 Jul;51(3):183-92
pubmed: 19002888
J Biotechnol. 2002 Jul 17;97(1):13-22
pubmed: 12052679
Biotechnol Bioeng. 2004 Mar 5;85(5):506-15
pubmed: 14760691
J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81
pubmed: 21987744
Expert Rev Vaccines. 2017 Sep;16(9):883-894
pubmed: 28724343
Biotechnol Prog. 2000 Sep-Oct;16(5):854-8
pubmed: 11027181
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Vaccine. 2004 Sep 28;22(29-30):3858-64
pubmed: 15364432
Vaccine. 2015 Nov 4;33(44):5905-12
pubmed: 26187258
Vaccine. 2015 Aug 20;33(35):4261-8
pubmed: 25862300
Vaccine. 2009 Oct 30;27(46):6464-7
pubmed: 19559123
Biotechnol J. 2015 May;10(5):728-40
pubmed: 25903999
Biotechnol Bioeng. 2018 May;115(5):1186-1194
pubmed: 29288575
Appl Biochem Biotechnol. 2013 Aug;170(7):1724-37
pubmed: 23737305
Biotechnol Bioeng. 2006 Jul 5;94(4):667-79
pubmed: 16570315
Sci Rep. 2018 Jan 12;8(1):644
pubmed: 29330501
Vaccine. 1998 May-Jun;16(9-10):960-8
pubmed: 9682344
J Gen Virol. 1979 Apr;43(1):247-52
pubmed: 113494
Bioprocess Biosyst Eng. 2015 Mar;38(3):543-55
pubmed: 25294335
Vaccine. 2018 Apr 12;36(16):2093-2103
pubmed: 29555218
Cytotechnology. 2003 May;42(1):1-11
pubmed: 19002923
Curr Protoc Microbiol. 2008 Nov;Appendix 4:Appendix 4E
pubmed: 19016439
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14802-7
pubmed: 19706449
Biotechnol Bioeng. 2010 Sep 1;107(1):143-53
pubmed: 20506276
Vaccine. 2006 Jan 30;24(5):652-61
pubmed: 16214268
Process Biochem. 2019 Jun;81:156-164
pubmed: 31217725
Genome Res. 2015 Dec;25(12):1921-33
pubmed: 26377836
PLoS One. 2008 Mar 19;3(3):e1810
pubmed: 18350148
Vaccine. 2007 May 10;25(19):3879-89
pubmed: 17307281
Biotechnol Bioeng. 2013 May;110(5):1354-65
pubmed: 23192424
PLoS One. 2013 Dec 12;8(12):e83374
pubmed: 24349497
Vaccine. 2019 Nov 8;37(47):7041-7051
pubmed: 31402239
Sci Data. 2017 Mar 01;4:170021
pubmed: 28248921
J Virol Methods. 2013 Oct;193(1):28-41
pubmed: 23684847
Dev Biol Stand. 1981;47:55-64
pubmed: 6785126
J Cell Sci. 1986 Mar;81:65-103
pubmed: 3733899
Vaccine. 2016 May 23;34(24):2700-6
pubmed: 27113161
Appl Microbiol Biotechnol. 2010 Sep;88(2):461-75
pubmed: 20617311
BMC Biotechnol. 2011 Aug 11;11:81
pubmed: 21835017
J Biosci Bioeng. 2011 May;111(5):600-4
pubmed: 21262586
Biotechnol Bioeng. 2020 Jun;117(6):1895-1903
pubmed: 32086804
Appl Biochem Biotechnol. 2010 Mar;160(6):1600-15
pubmed: 19504358
Vaccine. 2018 May 24;36(22):3134-3139
pubmed: 28274636
World J Gastroenterol. 2004 Sep 1;10(17):2571-3
pubmed: 15300909
Vaccine. 2014 May 19;32(24):2782-8
pubmed: 24583004
Vaccine. 2009 Apr 21;27(18):2513-22
pubmed: 19368794
PLoS One. 2015 Aug 19;10(8):e0136420
pubmed: 26287531
J Virol. 2015 Nov 18;90(4):1694-704
pubmed: 26581994
Biotechnol Prog. 2017 Jul;33(4):989-997
pubmed: 28054473
J Biomed Biotechnol. 2010;2010:586363
pubmed: 20625497
Vaccine. 2015 Aug 20;33(35):4288-91
pubmed: 25930117
World Health Organ Tech Rep Ser. 1987;747:1-29
pubmed: 3107222
Cytotechnology. 2012 Aug;64(4):429-41
pubmed: 22367019
Appl Microbiol Biotechnol. 2016 Mar;100(5):2121-32
pubmed: 26758296
Vaccine X. 2019 Jan 29;1:100009
pubmed: 31384731
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9
pubmed: 16617103
Vaccine. 2007 Jun 15;25(25):4845-52
pubmed: 17509734
Vaccine. 2019 Nov 8;37(47):6996-7002
pubmed: 31288997
Vaccine. 2009 Oct 30;27(46):6420-3
pubmed: 19559120
J Biotechnol. 2020 Feb 20;310:32-39
pubmed: 32006630
Nat Rev Cancer. 2018 Jul;18(7):419-432
pubmed: 29695749
Expert Rev Vaccines. 2015;14(9):1181-95
pubmed: 26178380
Biotechnol Prog. 2007 May-Jun;23(3):715-21
pubmed: 17461549
Cytotechnology. 1994;14(1):47-59
pubmed: 7765112
Vaccine. 2019 Nov 8;37(47):6987-6995
pubmed: 31201054
DNA Res. 2014 Dec;21(6):673-83
pubmed: 25267831
J Biotechnol. 2006 Jan 24;121(2):261-71
pubmed: 16153733
J Biotechnol. 2001 Dec 14;92(1):67-72
pubmed: 11604174
Braz J Med Biol Res. 1993 Dec;26(12):1305-17
pubmed: 8136732
Biotechnol Bioeng. 1999 Jan 5;62(1):12-9
pubmed: 10099508
PLoS One. 2017 Nov 27;12(11):e0188333
pubmed: 29176782
AMB Express. 2014 Apr 25;4:25
pubmed: 24949260
Vaccine. 2020 Apr 29;38(20):3639-3645
pubmed: 32247568
Virology. 2008 Apr 25;374(1):60-70
pubmed: 18221765
Biotechnol Prog. 1997 Jan-Feb;13(1):14-24
pubmed: 9041707
Biotechnol Prog. 2009 Nov-Dec;25(6):1752-61
pubmed: 19768803
Cytotechnology. 1997 Nov;25(1-3):35-44
pubmed: 22358877
Cytotechnology. 2001 Mar;35(2):115-25
pubmed: 19003288
Biotechnol Bioeng. 1996 Jun 20;50(6):627-35
pubmed: 18627071
mSphere. 2019 Jun 5;4(3):
pubmed: 31167947
Virol J. 2007 Feb 28;4:23
pubmed: 17328799
Vaccine. 2003 May 16;21(17-18):1867-73
pubmed: 12706671